Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103
Open Access
- 4 March 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 53 (13) , 6031-6040
Abstract
Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.Keywords
Funding Information
- Institut National des Sciences de l'Univers, Centre National de la Recherche Scientifique
- Institut National de la Santé et de la Recherche Médicale
- Conseil Régional des Pays de la Loire
- European Commission
This publication has 33 references indexed in Scilit:
- Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD‐100/KP1339 in the Endoplasmic ReticulumAngewandte Chemie International Edition, 2020
- Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasisCancer Letters, 2017
- Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell linesInvestigational New Drugs, 2016
- Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugsInvestigational New Drugs, 2015
- Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studiesJBIC Journal of Biological Inorganic Chemistry, 2012
- High resolution SPECT imaging for visualization of intratumoral heterogeneity using a SPECT/CT scanner dedicated for small animal imagingAnnals of Nuclear Medicine, 2011
- Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339JBIC Journal of Biological Inorganic Chemistry, 2010
- Tumor heterogeneity: Causes and consequencesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Radionuclides used for therapy and suggestion for new candidatesJournal of Radioanalytical and Nuclear Chemistry, 2005
- Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cellsJournal of Cancer Research and Clinical Oncology, 2004